CAS: 2095156-13-9

HSL-IN-1 is an HSL inhibitor that significantly reduces the reactive metabolite load and reduces the release of free fatty acids from stored fat.

HSL-IN-1 is an inhibitor analog of nalbuphine that has shown potential as an anticancer agent. It works by inhibiting the activity of certain kinases that are involved in tumor growth and survival. HSL-IN-1 induces apoptosis, or programmed cell death, in cancer cells by disrupting their protein synthesis and causing DNA damage. This compound has been found to be effective against a variety of human cancers, including breast, lung, and colon cancer. HSL-IN-1 is derived from Chinese medicinal urine and is one of several promising inhibitors currently being studied for their potential use as anticancer agents.